tbuckley/cabot-search huggingface dataset:
Return to the Workforce After First Hospitalization for Heart Failure
Authors: Rasmus Rørth, Chih Wong, Kristian Kragholm, Emil L. Fosbøl, Ulrik M. Mogensen, Morten Lamberts, Mark C. Petrie, Pardeep S. Jhund, Thomas A. Gerds, Christian Torp-Pedersen, Gunnar H. Gislason, John J.V. McMurray, Lars Køber, Søren L. Kristensen
Journal: Circulation (2016)

Return to work is important financially, as a marker of functional status and for self-esteem in patients developing chronic illness. We examined return to work after first heart failure (HF) hospitalization.By individual-level linkage of nationwide Danish registries, we identified 21 455 patients of working age (18-60 years) with a first HF hospitalization in the period from 1997 to 2012. Of these patients, 11 880 (55%) were in the workforce before HF hospitalization and comprised the study population. We applied logistic regression to estimate odds ratios for associations between age, sex, length of hospital stay, level of education, income, comorbidity, and return to work.One year after first HF hospitalization, 8040 (67.7%) returned to the workforce, 2981 (25.1%) did not, 805 (6.7%) died, and 54 (0.5%) emigrated. Predictors of return to work included younger age (18-30 versus 51-60 years; odds ratio [OR], 3.12; 95% confidence interval [CI], 2.42-4.03), male sex (OR, 1.22; 95% CI, 1.12-1.34), and level of education (long-higher versus basic school; OR, 2.06; 95% CI, 1.63-2.60). Conversely, hospital stay >7 days (OR, 0.56; 95% CI, 0.51-0.62) and comorbidity including history of stroke (OR, 0.55; 95% CI, 0.45-0.69), chronic kidney disease (OR, 0.46; 95% CI, 0.36-0.59), chronic obstructive pulmonary disease (OR, 0.62; 95% CI, 0.52-0.75), diabetes mellitus (OR 0.76; 95% CI, 0.68-0.85), and cancer (OR, 0.49; 95% CI, 0.40-0.61) were all significantly associated with lower chance of return to work.Patients in the workforce before HF hospitalization had low mortality but high risk of detachment from the workforce 1 year later. Young age, male sex, and a higher level of education were predictors of return to work.
Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of “Fol-Brite”
Authors: Frederick Lansigan, Eric Winer, Sara R Metzler, Lynn Shaw, Peggy Alton, Kate Foster, Todd MacKenzie, Anne W Beaven
Journal: Blood (2012)
I never asked to be ICE’d
Journal: BMJ (2016)

I never asked to be ICE'dA while ago I was talking with friends about the visit one of us recently had to make to her general practitioner."Don't you hate it when they ask you what you think is wrong?"she asked."I was tempted to say, 'why, don't you know?You're the bloody doctor.If I knew what was wrong already I wouldn't need the GP!"We'd all experienced something similar, and none of us could work out why our doctors were doing it.
Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma
Authors: Asim Afaq, Francesco Fraioli, Harbir Sidhu, Simon Wan, Shonit Punwani, Shih-hsin Chen, Oguz Akin, David Linch, Kirit Ardeshna, Jonathan Lambert, Kenneth Miles, Ashley Groves, Irfan Kayani
Journal: Clinical Nuclear Medicine (2016)

Purpose The primary aim was to compare the diagnostic performance of PET/MRI (performed with basic anatomical MRI sequences) in detecting sites of disease in adult patients with lymphoma compared with the current standard of care, PET/CT. Secondary aims were to assess the additional value of diffusion-weighted imaging to PET/MRI in disease detection and to evaluate the relationship between the standardized uptake value on PET/MR and the apparent diffusion coefficient on diffusion-weighted imaging. Methods Sixty-eight studies in 66 consecutive patients with histologically proven Hodgkin or non-Hodgkin lymphoma were prospectively evaluated. Each patient had whole body PET/CT, followed by whole body PET/MR. Two experienced readers independently evaluated the PET/MRI studies, and two other experienced readers independently evaluated PET/CT. Site of lymphoma involvement and SUVmax at all nodal sites more avid than background liver were recorded. Readers provided stage (in baseline cases) and disease status (remission vs active disease). The apparent diffusion coefficient mean value corresponding to the most avid PET site of disease was recorded. Results Ninety-five nodal and 8 extranodal sites were identified on both PET/CT and PET/MRI. In addition, 3 nodal and 1 extranodal sites were identified on PET/MRI. For positive lesion detection, reader agreement in PET/MR was perfect between the 2 readers and almost perfect between PET/CT and PET/MR (k > 0.978). Intermodality agreement between PET/CT and PET/MRI was also near perfect to perfect for staging/disease status k = (0.979–1.000). SUVmax from PET/CT and PET/MRI correlated significantly (Spearman rho correlation coefficient, 0.842; P < 0.001). Diffusion-weighted imaging did not alter lesion detection or staging in any case. A negative correlation was demonstrated between ADC mean and SUVmax (Spearman rho correlation coefficient r, −0.642; P < 0.001). Conclusions PET/MRI is a reliable alternative to PET/CT in the evaluation of patients with lymphoma. Diffusion-weighted imaging did not alter diagnostic accuracy. With comparable accuracy in detection of disease sites and added benefit of radiation dose reduction, PET/MRI has a potential to become part of routine lymphoma imaging.
The Presence of Alzheimer's Disease in a Community Population-Reply
Authors: Eric B. Larson
Journal: JAMA (1990)

<h3>In Reply.—</h3> The letters by Dr Bowden, Kokmen et al, and Dr Jarvik present important comments related to the East Boston study. Many of the points were alluded to in the original editorial, but several may benefit from restatement. Both Kokmen et al and Dr Bowden refer to the potential problem of the standards investigators use to determine cognitive dysfunction. Dysfunction may be related to low educational achievement or it may be related to so-called age-related decline. The most common cause of dementia—Alzheimer's disease—is characterized as acquired and progressive cognitive dysfunction. A cross-sectional survey—like the East Boston survey—cannot necessarily determine whether the dysfunction was acquired or is progressive because the assessment is made at a single point in time. Further, the investigators also did not have the opportunity to assess the functional consequences of cognitive impairment related to cognitive dysfunction. Nonetheless, the East Boston and other studies all demonstrate a
Pathogenesis of MONOSOMY 7 In BONE MARROW FAILURE SYNDROMES
Authors: Hideki Makishima, Fabiola Traina, Anna M Jankowska, Yuka Sugimoto, Kathryn M Guinta, Hirotoshi Sakaguchi, Christine L. O'Keefe, Hideki Muramatsu, Seiji Kojima, Jaroslaw P. Maciejewski
Journal: Blood (2011)
Suicide Attempt as a Risk Factor for Completed Suicide: Even More Lethal Than We Knew
Authors: J. Michael Bostwick, Chaitanya Pabbati, Jennifer R. Geske, Alastair J. McKean
Journal: American Journal of Psychiatry (2016)

While suicide attempt history is considered to robustly predict completed suicide, previous studies have limited generalizability because of using convenience samples of specific methods/treatment settings, disregarding previous attempts, or overlooking first-attempt deaths. Eliminating these biases should more accurately estimate suicide prevalence in attempters.This observational retrospective-prospective cohort study using the Rochester Epidemiology Project identified 1,490 (males, N=555; females, N=935) Olmsted County residents making index suicide attempts (first lifetime attempts reaching medical attention) between January 1, 1986, and December 31, 2007. The National Death Index identified suicides between enrollment and December 31, 2010 (follow-up 3-25 years). Medical records were queried for sex, age, method, and follow-up care for index attempt survivors. Coroner records yielded data on index attempt deaths.During the study period, 81/1,490 enrollees (5.4%) died by suicide. Of the 81, 48 (59.3%) perished on index attempt; 27 of the surviving 33 index attempt survivors (81.8%) killed themselves within a year. Males were disproportionately represented: 62/81 (11.2% of men, 76.5% of suicides) compared with 19/81 (2.0% of women, 23.5% of suicides). Of dead index attempters, 72.9% used guns, yielding an odds ratio for gunshot death, compared with all other methods, of 140 (95% CI=60-325). When adjusted for covariates, survivors given follow-up psychiatric appointments had significantly lower likelihood of subsequent suicide (odds ratio=0.212, 95% CI=0.089-0.507).At 5.4%, completed suicide prevalence in this community cohort of suicide attempters was almost 59% higher than previously reported. An innovative aspect of this study explains the discrepancy: by including index attempt deaths-approximately 60% of total suicides-suicide prevalence more than doubled. We contend that counting both index and subsequent attempt deaths more accurately reflects prevalence. Our findings support suicide attempt as an even more lethal risk factor for completed suicide than previously thought. Research should focus on identifying risk factors for populations vulnerable to making first attempts and target risk reduction in those groups.
Abstract 18655: Impact of New Guidelines on Atrial Fibrillation Pattern Classification: The Women’s Health Study
Authors: Jorge A Wong, Roopinder K Sandhu, David Conen, Christine M Albert
Journal: Circulation (2015)

Background: Recent US guidelines have updated atrial fibrillation (AF) pattern definitions, reclassifying patients who undergo successful cardioversion within 7 days of AF onset as paroxysmal rather than persistent. The impact of this reclassification on AF pattern designation and risk factor profiles in patients with AF is unknown. Methods: We examined all participants with confirmed, new-onset AF among 34,636 women who were aged ≥45 years and free of AF and cardiovascular disease at baseline within the Women’s Health Study. All women were classified by AF type using both 2006 and 2014 ACC/AHA AF guideline definitions. AF type was classified as the most sustained form within 2 years of initial diagnosis. Risk factor profiles of patients reclassified by the 2014 guidelines were then compared to patients where AF pattern classification remained unchanged. Results: During a median follow-up of 19.2 years, 1493 women developed incident AF. Application of the 2006 AF guidelines identified 998, 313 and 182 women with paroxysmal, persistent and permanent AF, respectively. Using the 2014 AF guidelines, 107 women with persistent AF (34.2%) were reclassified to paroxysmal. Compared to women classified as persistent by both guidelines, those reclassified to paroxysmal by the 2014 guidelines were younger and had a lower prevalence of hypertension; but had similar weight and BMI (Table). Compared to women classified as paroxysmal by both guidelines, the women reclassified to paroxysmal were again younger but had a higher weight and BMI. Other cardiac risk factors did not differ significantly across AF patterns (Table). Conclusions: Using 2014 AF guidelines definitions, AF pattern was reclassified in a significant number of persistent AF patients. The risk factor profile of the reclassified women differed with respect to age, hypertension and BMI; known risk factors for AF progression. Selected AF pattern definition may influence results of future studies on AF progression.
Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy
Authors: Carlota Recio, Iolanda Lazaro, Ainhoa Oguiza, Laura Lopez-Sanz, Susana Bernal, Julia Blanco, Jesus Egido, Carmen Gomez-Guerrero
Journal: Journal of the American Society of Nephrology (2016)

Diabetes is the main cause of CKD and ESRD worldwide. Chronic activation of Janus kinase and signal transducer and activator of transcription (STAT) signaling contributes to diabetic nephropathy by inducing genes involved in leukocyte infiltration, cell proliferation, and extracellular matrix accumulation. This study examined whether a cell-permeable peptide mimicking the kinase-inhibitory region of suppressor of cytokine signaling-1 (SOCS1) regulatory protein protects against nephropathy by suppressing STAT-mediated cell responses to diabetic conditions. In a mouse model combining hyperglycemia and hypercholesterolemia (streptozotocin diabetic, apoE-deficient mice), renal STAT activation status correlated with the severity of nephropathy. Notably, compared with administration of vehicle or mutant inactive peptide, administration of the SOCS1 peptidomimetic at either early or advanced stages of diabetes ameliorated STAT activity and resulted in reduced serum creatinine level, albuminuria, and renal histologic changes (mesangial expansion, tubular injury, and fibrosis) over time. Mice treated with the SOCS1 peptidomimetic also exhibited reduced kidney leukocyte recruitment (T lymphocytes and classic M1 proinflammatory macrophages) and decreased expression levels of proinflammatory and profibrotic markers that were independent of glycemic and lipid changes. In vitro, internalized peptide suppressed STAT activation and target gene expression induced by inflammatory and hyperglycemic conditions, reduced migration and proliferation in mesangial and tubuloepithelial cells, and altered the expression of cytokine-induced macrophage polarization markers. In conclusion, our study identifies SOCS1 mimicking as a feasible therapeutic strategy to halt the onset and progression of renal inflammation and fibrosis in diabetic kidney disease.
Highlights of the Year in JACC2006
Authors: Anthony N. DeMaria, Ori Ben-Yehuda, Gregory K. Feld, Geoffrey S. Ginsburg, Barry H. Greenberg, Wilbur Y.W. Lew, Joao A.C. Lima, Alan S. Maisel, Jagat Narula, David J. Sahn, Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2007)
Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis
Authors: Isis E. Fernandez, Flavia R. Greiffo, Marion Frankenberger, Julia Bandres, Katharina Heinzelmann, Claus Neurohr, Rudolf Hatz, Dominik Hartl, Jürgen Behr, Oliver Eickelberg
Journal: European Respiratory Journal (2016)

Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disease with irreversible lung function loss and poor survival. Myeloid-derived suppressor cells (MDSC) are associated with poor prognosis in cancer, facilitating immune evasion. The abundance and function of MDSC in IPF is currently unknown. Fluorescence-activated cell sorting was performed in 170 patients (IPF: n=69; non-IPF interstitial lung disease (ILD): n=56; chronic obstructive pulmonary disease (COPD): n=23; healthy controls: n=22) to quantify blood MDSC and lymphocyte subtypes. MDSC abundance was correlated with lung function, MDSC localisation was performed by immunofluorescence. Peripheral blood mononuclear cell (PBMC) mRNA levels were analysed by qRT-PCR. We detected increased MDSC in IPF and non-IPF ILD compared with controls (30.99±15.61% versus 18.96±8.17%, p≤0.01). Circulating MDSC inversely correlated with maximum vital capacity (r= −0.48, p≤0.0001) in IPF, but not in COPD or non-IPF ILD. MDSC suppressed autologous T-cells. The mRNA levels of co-stimulatory T-cell signals were significantly downregulated in IPF PBMC. Importantly, CD33 + CD11b + cells, suggestive of MDSC, were detected in fibrotic niches of IPF lungs. We identified increased MDSC in IPF and non-IPF ILD, suggesting that elevated MDSC may cause a blunted immune response. MDSC inversely correlate with lung function only in IPF, identifying them as potent biomarkers for disease progression. Controlling expansion and accumulation of MDSC, or blocking their T-cell suppression, represents a promising therapy in IPF.
Targeted cancer therapies: FDA approval overview.
Authors: P. Cortazar, P. Keegan, R. L. Justice, J. R. Johnson, R. Pazdur
Journal: Journal of Clinical Oncology (2010)

2537 Background: The development of targeted therapies requires the identification of molecular targets known to play a key role in cancer cell growth and survival. Methods: Review of clinical trials leading to new drug approvals for targeted cancer therapies. Results: The Table below summarizes the targeted cancer therapies approved by the FDA. Conclusions: Based on experience from the targeted cancer therapies currently approved, we conclude: (1) Molecular targets should optimally be identified prior to the initiation of registration trials. (2) In general, commercial tests to select patients with molecular markers should be validated concurrently with the drug development program. Exceptions may be in diseases where the molecular markers are expressed in the majority of patients such as CD20 antigens in follicular NHL and Bcr-Abl in CML. Molecular targets Approved drugs Indication Estrogen receptors SERMS: tamoxifen, toremifene, fulvestrant aromatase inhibitors: anastrozole,exemestane, letrozole Breast Bcr-Abl Imatinib mesylate, dasatinib, nilotinib CMLALL c-kit mutation Imatinib mesylate GIST EGFR Cetuximab, panitumumabgefitinib, erlotinib Colorectal, Lung CD-25 Deunileukin diftitox CTCL CD33Antigen Gemtuzumab ozogamicin CD33 + AML CD20 Rituximab, tositumomab +I131, ibritumomab, 90Y ofatumumab B-cell NHL CLL CD52 Alentuzumab B-cell CLL HER2 neu + Trastuzumab, lapatinib Breast Tyrosine kinases Sunitinib, pazopanib, sorafenib Renal cell, hepatocellular No significant financial relationships to disclose.
Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS).
Authors: K. Pietzner, R. G. Linke, M. Jäger, H. Lindhofer, H. Friccius-Quecke, F. Chen, E. I. Braicu, G. Oskay-Özcelik, J. Sehouli
Journal: Journal of Clinical Oncology (2010)

TPS155 Background: The trifunctional anti-EpCAM/anti-CD3 antibody catumaxomab has been recently approved in the EU for i.p. treatment of malignant ascites as one cycle of 4 i.p. applications within 11 days. As a growing number of clinicians are gathering experience with this antibody, the question arised, if a second treatment cycle could be feasible and effective for patients who did profit from the first cycle but eventually presented back with recurrent malignant ascites. Up to this point it remained unclear if human-anti-mouse-antibody (HAMA) would interfere with the efficiency of a second cycle, due to interception of the antibody. In a case of a patient with heavily pretreated breast cancer the patient was retreated with 4 i.p. applications of catumaxomab (10–20–50–150 μ g), which was well tolerated. HAMA-values were measured in the patients blood and ascites at different time intervals before, during and after this second cycle of catumaxomab. During this second treatment cycle a clear reduction of tumor cells and an increase of immune active cells in ascites samples could be observed, which was corresponding to a prolonged paracentesis free interval. This treatment effect was observed despite increasing HAMA response in the patients ascites and blood (340/1,627 ng/ml before and up to 587983/783893 ng/ml after treatment in ascites/plasma). On the basis of this first experience with a second cycle of catumaxomab in a patient, an open-label, single-arm phase II study was initialized. Methods: Systematic data concerning a second cycle of catumaxomab (10-20-50-150 μ g i.p.) are collected and analyzed in this study to investigate the safety, treatment effect, quality of life, pharmacokinetic, pharmakodynamics/immune status. In this roll-over concept up to 30 patients with a paracentesis free interval of at least 60 days after first cycle of catumaxomab within the randomized phase IIIb CASIMAS study (3h infusion; with versus without corticoid premedication) are included. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Fresenius Biotech, Fresenius Biotech GmbH, TRION Pharma, TRION Research, TRION Research GmbH Fresenius Biotech, GlaxoSmithKline TRION Pharma Fresenius Biotech
Treatment to Prevent Hepatitis B Virus Reactivation in Patients With Lymphoma Receiving Chemotherapy—Reply
Authors: Tongyu Lin, He Huang, Xueying Li
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnosis, treatment, and monitoring of dry eye disease
Authors: Eirini Skiadaresi, Jinhai Huang, Colm McAlinden
Journal: BMJ (2016)

The Drug and Therapeutics Bulletin ’s clinical review provides a stellar and punctilious overview of dry eye management.1 We would like to raise three pertinent points to complement this paper:

1.  Dry eye disease is associated with increased osmolarity of …